GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » Long-Term Debt

TSHA (Taysha Gene Therapies) Long-Term Debt : $43.94 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Taysha Gene Therapies Long-Term Debt?

Taysha Gene Therapies's Long-Term Debt for the quarter that ended in Dec. 2024 was $43.94 Mil.

Taysha Gene Therapies's quarterly Long-Term Debt increased from Jun. 2024 ($37.84 Mil) to Sep. 2024 ($42.97 Mil) and increased from Sep. 2024 ($42.97 Mil) to Dec. 2024 ($43.94 Mil).

Taysha Gene Therapies's annual Long-Term Debt increased from Dec. 2022 ($37.97 Mil) to Dec. 2023 ($40.51 Mil) and increased from Dec. 2023 ($40.51 Mil) to Dec. 2024 ($43.94 Mil).


Taysha Gene Therapies Long-Term Debt Historical Data

The historical data trend for Taysha Gene Therapies's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taysha Gene Therapies Long-Term Debt Chart

Taysha Gene Therapies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial - 37.19 37.97 40.51 43.94

Taysha Gene Therapies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.51 40.51 37.84 42.97 43.94

Taysha Gene Therapies  (NAS:TSHA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Taysha Gene Therapies Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Taysha Gene Therapies Business Description

Traded in Other Exchanges
N/A
Address
3000 Pegasus Park Drive, Suite 1430, Dallas, TX, USA, 75247
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Executives
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Alison S Long director KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kamran Alam officer: Chief Financial Officer 350 FIFTH AVENUE, SUITE 7530, NEW YORK NY 10118
Sean P. Nolan director C/O INTERMUNE, INC., 3280 BAYSHORE BLVD., BRISBANE CA 94005
Phillip B. Donenberg director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Session R.a. Ii 10 percent owner C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Sukumar Nagendran director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Astellas Pharma Inc. 10 percent owner 2-5-1, NIHONBASHI-HONCHO, CHUO-KU, TOKYO M0 103-8411
Audentes Therapeutics, Inc. 10 percent owner 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Suyash Prasad officer: CMO and Head of R&D C/O AUDENTES THERAPEUTICS, INC., 101 MONTGOMERY ST., SUITE 2650, SAN FRANCISCO CA 94104
Laura Sepp-lorenzino director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Kathleen Reape director C/O TAYSHA GENE THERAPIES, INC., 2280 INWOOD ROAD, DALLAS TX 75235